Clinical Trials Sponsored by Apitope International NV

Total 76 results

Apitope International NV
Quintiles, Inc.; European Commission

Completed

ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

Graves Disease

United Kingdom
Janssen-Cilag International NV

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

Schizophrenia

France, United Kingdom, Belgium, Germany, Spain, Portugal, Bulgaria, Serbia, Switzerland, Israel, Finland, Greece, Sweden, Russian Federation, Netherlands, Denmark, Hungary, Lithuania, Latvia, Croatia, Turkey, Poland
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (SALIF)

Human Immunodeficiency Virus-type 1 Infection

South Africa, Kenya, Thailand, Uganda, Cameroon, Senegal
Janssen-Cilag International NV

Completed

Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants

Healthy

Netherlands
Janssen-Cilag International NV

Terminated

A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis

Gastroenteritis

Spain, Belgium, South Africa, Russian Federation, Austria, United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

Healthy

Belgium
Janssen-Cilag International NV

Completed

Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (OPTIMRETREAT)

Multiple Myeloma

France, Poland, Belgium, Germany, Israel, Portugal, Turkey, Finland, Sweden, Netherlands, Norway
Janssen-Cilag International NV

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

Velcade Consolidation Bone Study

Multiple Myeloma

Turkey, Greece, Czech Republic, Austria, Germany, Sweden, United Kingdom, Denmark
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
Janssen-Cilag International NV

Completed

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

France, Germany, Bulgaria, Greece, Russian Federation
Janssen-Cilag International NV

Completed

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD (SEQUENTIAL)

Multiple Myeloma

France, United Kingdom, Spain, Poland, Serbia, Turkey, Greece, Germany, Hungary, Lithuania
Janssen-Cilag International NV

Completed

A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate (TRANSIT)

Psoriasis

France, Germany, Poland, United Kingdom, Spain, Belgium, Portugal, Bulgaria, Greece, Israel, Sweden, Netherlands, Austria, Hungary, Lithuania, Slovakia, Denmark, Finland, Norway
Janssen-Cilag International NV

Completed

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Schizophrenia

Spain, Argentina, Romania, South Africa, Turkey, Greece, Lithuania, Slovakia, Latvia, Estonia, France, Egypt, Lebanon, Jordan
Janssen-Cilag International NV

Completed

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia

France, Poland, Germany, Spain, Slovenia, Bulgaria, Romania, Israel, Greece, Sweden, Turkey, Czech Republic, Hungary, Lithuania, Latvia, Portugal, Croatia, Slovakia, Austria, United Kingdom, Estonia, Ireland, Denmark, Saudi Arabia
Janssen-Cilag International NV

Completed

Paliperidone Palmitate Flexible Dosing in Schizophrenia (PALMFlexS)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Spain, Israel, Portugal, Turkey, Greece, Sweden, Belgium, Netherlands, Hungary, Denmark, Lithuania, Latvia, Croatia, Estonia, Austria, Switzerland
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Janssen-Cilag International NV

Active, not recruiting

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (GUIDE)

Psoriasis

Germany, France
Janssen-Cilag International NV

Active, not recruiting

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (CASPAR)

Schizophrenia

Rwanda
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
Janssen-Cilag International NV

Terminated

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Kidney Failure, Chronic

Germany
Janssen-Cilag International NV

Completed

A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)

Respiratory Tract Infections

Germany, Spain
Janssen-Cilag International NV

Withdrawn

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant
Janssen-Cilag International NV

Completed

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Schizophrenia

Germany, Spain, Belgium, Hungary, France, Italy, United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

Healthy

Germany
Janssen-Cilag International NV

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Healthy

United Kingdom
Janssen-Cilag International NV

Completed

A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen-Cilag International NV

Completed

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan (CRATOS)

Diabetes Mellitus, Type 2

United Arab Emirates, Lebanon, Kuwait
Janssen-Cilag International NV

Completed

Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. (PROFILE)

Gastroesophageal Reflux Disease | GERD | Gastro-oesophageal Reflux | Gastro-Esophageal Reflux | Esophageal Reflux
Janssen-Cilag International NV

Completed

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

Healthy

Netherlands
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Janssen-Cilag International NV

Completed

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Healthy

Germany
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
Janssen-Cilag International NV

Completed

Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

Healthy

Germany
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Janssen-Cilag International NV

Recruiting

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (STELARA)

Psoriasis

Belgium, United Kingdom, Austria, Denmark, France, Germany, Netherlands, Norway, Russian Federation, Switzerland, Greece
Janssen-Cilag International NV

Completed

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

Major Depressive Disorder

Belgium, Germany, Netherlands
Janssen-Cilag International NV

Completed

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

Hepatic Impairment

Germany
Janssen-Cilag International NV

Completed

A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
Janssen-Cilag International NV

Completed

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

Healthy

Belgium

3

Subscribe